Furthermore, we subdivided patients according to discharge Hb and found increased mortality risks in patients with only mildly reduced Hb concentration and a dose-response effect that resulted in progressively lower survival rates with more profound degrees of anemia. This evidence concerns the gene GSTM1 and anemia.